664-GENEVA: Modeling KRAS Inhibitor Responses
The paper introduces GENEVA, a scalable single-cell resolution platform designed to improve the accuracy of preclinical cancer drug testing. By creating mosaic tumor models that blend diverse patient-derived and cancer cell lines into single experiments, the platform captures how different genetic backgrounds respond to treatments simultaneously. Applying this technology to KRAS-G12C inhibitors, researchers discovered that mitochondrial hyperactivation drives cell death while epithelial-to-mesenchymal transition acts as a specific resistance mechanism in living models. These high-resolution…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.